Supplemental digital content 1: Characteristics of the men and women from the ETRAL study at baseline

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Men (n=117)** | **Women (n=48)** | **P-value** |
| **Age** (years) median (IQR) | 53 (49-58) |  50 (47-58) | 0.113 |
| **Origin** n (%) |  |  | **<0.001** |
| **Caucasian** | 98 (83.8)  | 26 (54.2)  |  |
| **Black African** | 7 (6.0)  |  17 (35.4) |  |
| **others** | 12 (10.2)  |  5 (10.4) |  |
| **Years of HIV diagnosis,** median (IQR) |  1995 (1990-2002) | 1995 (1991-2003)  | 0.890 |
| **Time since HIV diagnosis** (years) median (IQR) | 20 (13-25) | 20 (12-24) | 0.961 |
| **ART duration** (years) median (IQR) |  17 (11-19) | 17 (11-19)  | 0.960 |
| **CD4 cell count at baseline** (cells/mm3), median (IQR) |  693 (529-888) | 722 (539-916)  | 0.391 |
| **CD8 cell count at baseline** (cells/mm3), median (IQR) |  775 (576-1002) |  604 (458-845) | **0.005** |

Supplemental digital content 2: Hormonal parameters in women according to the ovarian activity/menopausal status at baseline and 48 weeks after switch

AMH : anti-Müllerian hormone, DHEA: dehydroepiandrosterone

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **n** | **Baseline** | **W48** | **P value** **BL vs W48** | **P value** **group1 vs 3 W48** |
| **AMH**  | Functional ovarian activity  | 12 | 0.172 (0.075-0.29) | 0.152 (0.034-0.40) | 0.677 |  **<0.0001** |
|  ng/ml | Perimenopausal | 6 | 0.009 (0.008-0.012) | 0.008 (0.006-0.01) | 0.375 |  |
|  | Postmenopausal | 21 | 0.009 (0.008-0.0095) | 0.005 (0.004-0.007) | **0.042** |  |
|   | P-value between groups |   | **<0.0001** | **<0.0001** |  |   |
| **Estradiol**  | Functional ovarian activity | 12 | 84.5 (62.5-142.3) | 61.5 (38.5-88.5) | 0.769 |  **<0.0001**  |
|  pg/ml | Perimenopausal | 6 | 45 (12.25-192.5) | 10 (10-32.5) | 0.187 |  |
|  | Pos-menopausal | 21 | 11 (10-16) | 10 (10-18) | **0.0002** |  |
|   | P-value between groups |   | **<0.0001** | **<0.0001**  |  |   |
| **Progesterone**  | Functional ovarian activity | 10 | 0.16 (0.065-5.75) | 0.23 (0.06-2.51) | 0.625 |  **0.003**  |
| ng/ml | Perimenopausal | 6 | 0.37 (0.11-4.43) | 0.045 (0.04-0.095) | 0.0625 |  |
|  | Postmenopausal | 19 | 0.06 (0.04-0.09) | 0.04 (0.03-0.06) | 0.196 |  |
|  | P-value between groups |  | **0.008**  | **0.012** |  |  |
| **Testosterone**  | Functional ovarian activity | 10 | 0.18 (0.155-0.23) | 0.21 (0.16-0.325) | 0.168 |  0.301 |
| ng/ml | Perimenopausal | 6 | 0.175 (0.15-0.2) | 0185 (0.12-0.205) | 0.750 |  |
|  | Postmenopausal | 19 | 0.14 (0.09-0.22) | 0.17 (0.15-0.26) | **0.043** |  |
|  | P-value between groups |  | 0.495 | 0.395  |  |  |
| **Androstenedione**  | Functional ovarian activity | 10 | 0.425 (0.36-0.61) | 0.625 (0.4-0.965) | **0.037** | **0.046**  |
| ng/ml | Perimenopausal | 6 | 0.41 (0.35-0.48) | 0.33 (0.28-0.54) | 0.750 |  |
|  | Postmenopausal | 19 | 0.37 (0.19-0.50) | 0.44 (0.32-0.60) | 0.358 |  |
|  | P-value between groups |  | 0.411  | 0.104  |  |  |
| **DHEA** ng/ml | Functional ovarian activity | 9 | 0.73 (0.285-0.97) | 1.465 (1.04-2.18) | 0.074 | 0.250  |
|  | Perimenopausal | 6 | 1.3 (0.55-4.925) | 0.98 (0.47-1.48) | 0.219 |  |
|  | Postmenopausal | 17 | 1.24 (0.355-1.98) | 0.69 (0.09-2.74) | 0.284 |  |
|  | P-value between groups |  | 0.272 | 0.334  |  |  |